⚕ GalenOps CRO console
← SITE014 (NLD)

SITE014-0311

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE014 (NLD) (Dr. Moreau) · consented 2023-02-27
Adverse events
9
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-04-18 (study day 34); relationship: N

moderate assessed 2026-08-18

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-05-23 (study day 69); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-06-08 (study day 85); relationship: N

mild assessed 2026-08-18

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-07-13 (study day 120); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-09-24 (study day 193); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-11-06 (study day 236); relationship: N

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-12-02 (study day 262); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-12-09 (study day 269); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-01-19 (study day 310); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.